Dopamine receptor D4 subtype (DRD4)

Dopamine receptor D4 subtype is a G protein-coupled receptor encoded by the *DRD4* gene, primarily expressed in the prefrontal cortex and hippocampus, with lower levels in other brain regions compared to other dopamine receptors[1][2][7]. It is activated by dopamine and couples to Gi/o proteins, thereby inhibiting adenylyl cyclase and reducing intracellular cAMP[1][7]. The receptor plays critical roles in modulating cognition, attention, impulsivity, novelty seeking, and compulsivity—traits relevant to various neuropsychiatric and behavioral disorders such as ADHD, schizophrenia, addiction, and personality traits[1][2][3][4]. DRD4 is highly polymorphic, especially in its third intracellular loop, affecting receptor function and disease susceptibility[3][4]. The D4 receptor is a validated therapeutic target for pharmacological treatment of schizophrenia, ADHD, Parkinson’s disease, and, emerging research suggests, other impulse control disorders[1][2][3][4][6]. Several selective ligands and antipsychotic drugs have been identified that act on DRD4, with discovery efforts supported by receptor crystal structures and computational docking methods[6].

Other names

DRD4Dopamine D4 receptorD4 dopamine receptor

Agonists/antagonists modulate receptor signaling, typically by inhibiting adenylyl cyclase, lowering cAMP levels Modulation of attention, impulsivity, and novelty seeking via postsynaptic effects in prefrontal cortex and hippocampus Some antipsychotics act as antagonists at D4 receptors Certain compounds show selective partial agonism or biased signaling (e.g., preferential G protein or β-arrestin pathways)